In this issue:
An individualised mRNA-based neoantigen vaccine in TNBC
Survival with complementary/alternative medicine in breast cancer
Supplemental breast MRI according to risk/tissue density
An AI model to estimate Oncotype DX recurrence scores
TBCRC 035: reduced-dose palbociclib + endocrine therapy in HR+/HER2–breast cancer
Brain MRI screening in HER2+ breast cancer/TNBC
VIKTORIA-1: gedatolisib + fulvestrant ± palbociclib in HR+/HER2−/PIK3CA wild-type breast cancer
Survival with/without risk-reducing mastectomy in BRCA1/2 carriers
SOLTI-1716 TATEN: pembrolizumab + paclitaxel in HR+/HER2− breast cancer classified as HER2-enriched or basal-like
EMBER-3: updated OS analysis of imlunestrant ± abemaciclib in HR+/HER2− breast cancer
Please login below to download this issue (PDF)